Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties

Environmental Research

Volumn 113, Issue , 2012, Pages 52-57

  Gong, Gordon ^a   O'Bryant, Sid E ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b University of North Texas Health Science Center   (United States)

Author keywords

Arsenic; AS3MT; Heart; Hyperlipidemia; Hypertension

Indexed keywords

ANTILIPEMIC AGENT; ARSENIC; GROUND WATER;

ARSENIC; CARDIOVASCULAR DISEASE; DRINKING WATER; ETHNICITY; GROUNDWATER POLLUTION; HEALTH RISK; HYPERTENSION; MORTALITY; POLLUTION EXPOSURE; POLYMERIZATION; PUBLIC HEALTH; RISK FACTOR; RURAL AREA;

ADULT; AGE; AGED; ALCOHOLISM; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EDUCATIONAL STATUS; ENVIRONMENTAL EXPOSURE; ETHNICITY; FEMALE; GENOTYPE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RURAL AREA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; UNITED STATES; WATER CONTAMINATION;

ADULT; AGED; AGED, 80 AND OVER; ARSENIC; COHORT STUDIES; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING WATER; ENVIRONMENTAL EXPOSURE; FEMALE; GROUNDWATER; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LOGISTIC MODELS; MALE; METHYLTRANSFERASES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RURAL HEALTH; TEXAS; WATER POLLUTANTS, CHEMICAL;

TEXAS; UNITED STATES;

EID: 84857642813     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2012.01.003     Document Type: Article

References (62)

1. Agusa T., Fujihara J., Takeshita H., Iwata H. Individual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms. Int. J. Mol. Sci. 2011, 12:2351-2382.
2. Aposhian H.V., Zakharyan R.A., Avram M.D., Sampayo-Reyes A., Wollenberg M.L. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol. Appl. Pharmacol. 2004, 198:327-335.
3. AvRuskin G.A., Jacquez G.M., Meliker J.R., Slotnick M.J., Kaufmann A.M., Nriagu J.O. Visualization and exploratory analysis of epidemiologic data using a novel space time information system. Int. J. Health Geogr. 2004, 3:26.
4. Benbrahim-Tallaa L., Waalkes M.P. Inorganic arsenic and human prostate cancer. Environ. Health Perspect. 2008, 116:158-164.
5. Celik I., Gallicchio L., Boyd K., Lam T.K., Matanoski G., Tao X., et al. Arsenic in drinking water and lung cancer: a systematic review. Environ. Res. 2008, 108:48-55.
6. Chang C.C., Ho S.C., Tsai S.S., Yang C.Y. Ischemic heart disease mortality reduction in an arseniasis-endemic area in southwestern Taiwan after a switch in the tap-water supply system. J. Toxicol. Environ. Health A 2004, 67:1353-1361.
7. Chen B., Arnold L.L., Cohen S.M., Thomas D.J., Le X.C. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol. Sci.. Sep 20. [Epub ahead of print] 2011.
8. Chen C.J., Chiou H.Y., Chiang M.H., Lin L.J., Tai T.Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler. Thromb. Vasc. Biol. 1996, 16:504-510.
9. Chen C.J., Wu M.M., Lee S.S., Wang J.D., Cheng S.H., Wu H.Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988, 8:452-460.
10. Chiu H.F., Ho S.C., Wang L.Y., Wu T.N., Yang C.Y. Does arsenic exposure increase the risk for liver cancer?. J. Toxicol. Environ. Health A 2004, 67:1491-1500.
11. Chung C.J., Hsueh Y.M., Bai C.H., Huang Y.K., Huang Y.L., Yang M.H., et al. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Control 2009, 20:1653-1661.
12. Ciambrone G., Kaski J.C. The importance of gender differences in the diagnosis and management of cardiovascular disease. Curr. Pharm. Des. 2011, 17:1079-1081.
13. Collins A., Morton N.E. Mapping a disease locus by allelic association. Proc. Natl. Acad. Sci. USA 1998, 95:1741-1745.
14. Das A.K., Sahu R., Dua T.K., Bag S., Gangopadhyay M., Sinha M.K., Dewanjee S. Arsenic-induced myocardial injury: protective role of Corchorus olitorius leaves. Food Chem. Toxicol. 2010, 48:1210-1217.
15. Ebrahim S., Taylor F., Ward K., Beswick A., Burke M., Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst. Rev. 2011, Jan19(1). CD001561.
16. Engström K., Vahter M., Mlakar S.J., Concha G., Nermell B., Raqib R., et al. Polymorphisms in arsenic (+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 2011, 119:182-188.
17. Engström S.K., Broberg K., Concha G., Nermell B., Warholm M., Vahter M. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect. 2007, 115:599-605.
18. ESRI,2009.ArcGIS. Available: 〈〉 [accessed 25 April 2011]. http://www.esri.com/.
19. Ferdinand K.C. Cardiovascular disease in blacks: can we stop the clock?. J. Clin. Hypertens. (Greenwich) 2008, 10:382-389.
20. Fujihara J., Fujii Y., Agusa T., Kunito T., Yasuda T., Moritani T., et al. Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol. Appl. Pharmacol. 2009, 234:41-46.
21. Garelick H., Jones H., Dybowska A., Valsami-Jones E. Arsenic pollution sources. Rev. Environ. Contam. Toxicol. 2008, 197:17-60.
22. Gebel T.W. Arsenic methylation is a process of detoxification through accelerated excretion. Int. J. Hyg. Environ. Health 2002, 205:505-508.
23. Gong G., O'Bryant S.E. The arsenic exposure hypothesis for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010, 24:311-316.
24. Healy S.M., Wildfang E., Zakharyan R.A., Aposhian H.V. Diversity of inorganic arsenite biotransformation. Biol. Trace Elem. Res. 1999, 68:249-266.
25. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 1990, 31:545-548.
26. Jomova K., Jenisova Z., Feszterova M., Baros S., Liska J., Hudecova D., Rhodes C.J., Valko M. Arsenic: toxicity, oxidative stress and human disease. J. Appl. Toxicol. 2011, 31:95-107.
27. Khan N.I., Owens G., Bruce D., Naidu R. Human arsenic exposure and risk assessment at the landscape level: a review. Environ. Geochem. Health 2009, 31(Suppl. 1):143-166.
28. Kullo J.I., Keyue Ding K. Mechanisms of disease: the genetic basis of coronary heart disease. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:558-569.
29. Lautenberger J.A., Stephens J.C., O'Brien S.J., Smith M.W. Significant admixture linkage disequilibrium across 30cM around the FY locus in African Americans. Am. J. Hum. Genet. 2000, 66:969-978.
30. Leuzzi C., Modena M.G. Coronary artery disease: clinical presentation, diagnosis and prognosis in women. Nutr. Metab. Cardiovasc. Dis. 2010, 20:426-435.
31. Liao C.M., Shen H.H., Chen C.L., Hsu L.I., Lin T.L., Chen S.C., Chen C.J. Risk assessment of arsenic-induced internal cancer at long-term low dose exposure. J. Hazard. Mater. 2009, 165:652-663.
32. Lopez-Ruiz A., Sartori-Valinotti J., Yanes L.L., Iliescu R., Reckelhoff J.F. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H466-474.
33. Medrano M.A., Boix R., Pastor-Barriuso R., Palau M., Damián J., Ramis R., Del Barrio J.L., Navas-Acien A. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ. Res. 2010, 110:448-454.
34. Meliker J.R., Wahl R.L., Cameron L.L., Nriagu J.O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health 2007, 6:4.
35. Mink P.J., Alexander D.D., Barraj L.M., Kelsh M.A., Tsuji J.S. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Regul. Toxicol. Pharmacol. 2008, 52:299-310.
36. Mittal S. Coronary Heart Disease in Clinical Practice 2005, Springer-Verlag, London, pp.107-150.
37. National Research Council Subcommittee to Update the 1999ArsenicinDrinking Water Report, Committee on Toxicology, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies. Arsenic in Drinking Water, 2001 update. Washington, DC.National Academy Press.
38. O'Bryant S.E., Edwards M., Menon C.V., Gong G., Barber R. Long-term low-level arsenic exposure is associated with poorer neuropsychological functioning: a project FRONTIER study. Int. J. Environ. Res. Public Health 2011, 8:861-874.
39. O'Bryant S.E., Zhang Y., Owen D., Cherry B., Ramirez V., Silva M., Hudson C., Hobson V., Grammas P., Schiffer R.B., Manning G., Schrimsher G.W., Lucas J.A., Sutker P.B. The cochran county aging study: Methodology and descriptive statistics. Tex. Public Health J. 2009, 61:5-7.
40. Paramsothy P., Knopp R., Bertoni A.G., Tsai M.Y., Rue T., Heckbert S.R. Combined hyperlipidemia in relation to race/ethnicity, obesity, and insulin resistance in the multi-ethnic study of atherosclerosis. Metabolism 2009, 58:212-219.
41. Park J.P., Park M.K., Yun J.W. Proteomic biomarkers for diagnosis in acute myocardial infarction. Biomarkers 2011, 16:1-11.
42. Petrick J.S., Jagadish B., Mash E.A., Aposhian H.V. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem. Res. Toxicol. 2001, 14:651-656.
43. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., Aposhian H.V. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 2000, 163:203-207.
44. Rahman M.M., Ng J.C., Naidu R. Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ. Geochem. Health 2009, 31(Suppl. 1):189-200.
45. Rondeau V., Jacqmin-Gadda H., Commenges D., Helmer C., Dartigues J.F. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am. J. Epidemiol. 2009, 169:489-496.
46. RykerS.2001.Mapping arsenic in groundwater. Available: 〈〉 [accessed 25 April 2011]. http://www.agiweb.org/geotimes/nov01/feature_Asmap.html/.
47. Samadder S.R., Subbarao C. GIS approach of delineation and risk assessment of areas affected by arsenic pollution in drinking water. J. Environ. Eng. 2007, 133:742-749.
48. Smith A.H., Lopipero P.A., Bates M.N., Steinmaus C.M. Arsenic epidemiology and drinking water standards. Science 2002, 296:2145-2146.
49. States J.C., Srivastava S., Chen Y., Barchowsky A. Arsenic and cardiovascular disease. Toxicol. Sci. 2009, 107:312-323.
50. Steinmaus C., Yuan Y., Kalman D., Rey O.A., Skibola C.F., Dauphine D., et al. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol. Appl. Pharmacol. 2010, 247:138-145.
51. Su C.C., Lin Y.Y., Chang T.K., Chiang C.T., Chung J.A., Hsu Y.Y., et al. Incidence of oral cancer in relation to nickel and arsenic concentrations in farm soils of patients' residential areas in Taiwan. BMC Public Health 2010, 10:67.
52. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., et al. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. 2007, 232:3-13.
53. Thomas D.J., Styblo M., Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 2001, 176:127-144.
54. Tseng C.H., Chong C.K., Tseng C.P., Hsueh Y.M., Chiou H.Y., Tseng C.C., et al. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol. Lett. 2003, 137:15-21.
55. Vahidnia A., van der Voet G.B., de Wolff F.A. Arsenic neurotoxicity-a review. Hum. Exp. Toxicol. 2007, 26:823-832.
56. Valenzuela O.L., Drobná Z., Hernández-Castellanos E., Sánchez-Peña L.C., García-Vargas G.G., Borja-Aburto, et al. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol. Appl. Pharmacol. 2009, 239:200-207.
57. Valko M., Morris H., MTD Cronin Metals, toxicity and oxidative stress. Curr. Med. Chem. 2005, 12:1161-1208.
58. Wang C.H., Jeng J.S., Yip P.K., Chen C.L., Hsu L.I., Hsueh Y.M., et al. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 2002, 105:1804-1809.
59. Wu M.M., Chiou H.Y., Chen C.L., Wang Y.H., Hsieh Y.C., Lien L.M., Lee T.C., Chen C.J. GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol. Appl. Pharmacol. 2010, 248:226-233.
60. Yuan Y., Marshall G., Ferreccio C., Steinmaus C., Selvin S., Liaw J., et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am. J. Epidemiol. 2007, 166:1381-1391.
61. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol. Sci. 2011, 121:257-266.
62. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (+3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol. Appl. Pharmacol. 2010, 246:1-7.